Form 8-K - Current report:
SEC Accession No. 0001193125-26-234882
Filing Date
2026-05-21
Accepted
2026-05-21 17:12:40
Documents
13
Period of Report
2026-05-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d162035d8k.htm   iXBRL 8-K 31178
2 EX-99.1 d162035dex991.htm EX-99.1 79644
  Complete submission text file 0001193125-26-234882.txt   268283

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA snse-20260521.xsd EX-101.SCH 3212
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE snse-20260521_def.xml EX-101.DEF 13741
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE snse-20260521_lab.xml EX-101.LAB 22528
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE snse-20260521_pre.xml EX-101.PRE 14557
16 EXTRACTED XBRL INSTANCE DOCUMENT d162035d8k_htm.xml XML 5387
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39980 | Film No.: 261009852
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)